AstraZeneca Offers Outcomes-Based Pricing for Symbicort

US health insurance company Highmark has negotiated an outcomes-based pricing agreement for AstraZeneca’s respiratory drug, Symbicort. The inhaler is used to treat patients with asthma and chronic obstructive pulmonary disease (COPD) and improves airway function by decreasing inflammation in the lungs.